1. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;J Clin Oncol,2015
2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015
3. Activity and safety of Nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015
4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei,2015
5. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015